Monitoring and Evaluation
A clinical nurse with the Ghana Health Service reviews case management data with a colleague, who enters the data into a cell phone for analysis. Ongoing monitoring of data is used to improve programs, while periodic evaluations are used to determine whether a program is reaching its goals. Source: Meaghan O’Keefe/PMI |
PMI was launched in June 2005 as a five-year, $1.2 billion initiative to rapidly scale up malaria prevention and treatment interventions and reduce malaria-related mortality by 50 percent in 15 high-burden countries in sub-Saharan Africa. A comprehensive five-year evaluation of PMI was conducted in 2011. In addition, PMI is supporting a series of evaluations of impact in all PMI focus countries.
As part of the 2010 USG Malaria Strategy [PDF, 483KB], an expanded PMI strategy for 2009-2014 was developed to achieve Africa-wide impact. The goal is to halve the burden of malaria in 70 percent of at-risk populations in sub-Saharan Africa, i.e., approximately 450 million residents.
The goal to reduce the burden of malaria will be achieved by reaching and sustaining 85 percent coverage of the most vulnerable groups – children under five years of age and pregnant women – with proven preventive and therapeutic interventions, including artemisinin-based combination therapies (ACTs), insecticide-treated nets (ITNs), intermittent preventive treatment of pregnant women (IPTp), and indoor residual spraying (IRS). PMI has a single set of country-level targets for the four major control measures, which are the same for each focus country:
- More than 90 percent of households with a pregnant woman and/or child under five will own one or more ITNs;
- 85 percent of children under five will have slept under an ITN the previous night;
- 85 percent of pregnant women will have slept under an ITN the previous night;
- 85 percent of houses in geographic areas targeted for IRS will have been sprayed;
- 85 percent of pregnant women and children under five will have slept under an ITN the previous night or in a house that has been protected by IRS;
- 85 percent of women (in areas determined to be appropriate for IPTp use) who have completed a pregnancy in the last two years will have received two or more doses of sulfadoxine-pyrimethamine (SP) for IPTp during that pregnancy; and
- 85 percent of government health facilities will have ACTs available for the treatment of uncomplicated malaria *
Resources
- PMI Monitoring and Evaluation Strategy [PDF, 181KB]
This document provides a detailed description of how PMI is monitoring and evaluating programs in PMI focus countries. - PMI Monitoring and Evaluation Indicators [PDF, 177KB]
This table includes the full set of indicators to be used for monitoring and evaluation of PMI. - PMI End-Use Verification Tool [PDF, 476KB]
This PMI-supported survey questionnaire is being implemented to monitor the availability of malaria commodities at the health facility level in PMI focus countries. - Roll Back Malaria Monitoring and Evaluation Toolbox
- Roll Back Malaria Monitoring and Evaluation Reference Group (MERG)